International Journal of Radiation Oncology * Biology * Physics
Volume 71, Issue 1 , Pages 16-22 , 1 May 2008

Effect of Increasing Radiation Doses on Local and Distant Failures in Patients With Localized Prostate Cancer

  • Patrick A. Kupelian, M.D.

      Affiliations

    • Department of Radiation Oncology, M.D. Anderson Cancer Center Orlando, Orlando, FL
    • Corresponding Author InformationReprint requests to: Patrick Kupelian, M.D., Department of Radiation Oncology, M.D. Anderson Cancer Center Orlando, 1400 S. Orange Ave., Orlando FL 32806. Tel: (407) 841-8666; Fax: (407) 649-6895
    • ,
  • Jay Ciezki, M.D.

      Affiliations

    • Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH
    • ,
  • Chandana A. Reddy, M.S.

      Affiliations

    • Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH
    • ,
  • Eric A. Klein, M.D.

      Affiliations

    • Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH
    • ,
  • Arul Mahadevan, M.D.

      Affiliations

    • Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH

Received 26 July 2007 ,Revised 30 August 2007 ,Accepted 7 September 2007.

References 

  1. Kupelian P, Kuban D, Thames H, et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys. 2005;61:415–419
  2. Kupelian PA, Mohan DS, Lyons J, et al. Higher than standard radiation doses (72 Gy or greater) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000;46:567–574
  3. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–1105
  4. Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491–500
  5. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA. 2005;294:1233–1239
  6. D'Amico AV, Whittington R, Malkowicz SB, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1999;17:168–172
  7. Kupelian PA, Thakkar VV, Khuntia D, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes. Int J Radiat Oncol Biol Phys. 2005;63:1463–1468
  8. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  9. Morgan PB, Hanlon AL, Horwitz EM, et al. Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys. 2007;67:1074–1081
  10. Horwitz EM, Thames HD, Kuban DA, et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: A multi-institutional pooled analysis. J Urol. 2005;173:797–802
  11. Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003;57:929–943
  12. Pollack A, Hanlon AL, Movsas B, et al. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:19–23
  13. Pickles T. Prostate-specific antigen (PSA) bounce and other fluctuations: Which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy. Int J Radiat Oncol Biol Phys. 2006;64:1355–1359
  14. Williams SG, Duchesne GM, Gogna NK, et al. An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk. Int J Radiat Oncol Biol Phys. 2006;65:351–357
  15. Williams SG, Pickles T, Kestin L, et al. A multicenter study demonstrating discordant results from electronic prostate-specific antigen biochemical failure calculation systems. Int J Radiat Oncol Biol Phys. 2006;65:1494–1500
  16. Lyons JA, Kupelian PA, Mohan DS, et al. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology. 2000;55:85–90
  17. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111–1116
  18. Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006;176:1415–1419
  19. Peeters ST, Hoogeman MS, Heemsbergen WD, et al. Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: Normal tissue complication probability modeling. Int J Radiat Oncol Biol Phys. 2006;66:11–19
  20. Michalski JM, Winter K, Purdy JA, et al. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys. 2003;56:192–198
  21. Teh B, Uhl B, Augspurger M, et al. Intensity-modulated radiotherapy (IMRT) for localized prostate cancer: Preliminary results of acute toxicity compared to conventional and six-field conformal approach. [Abstract] Int J Radiat Oncol Biol Phys. 1998;42(Suppl. 1):219
  22. Stock RG, Stone NN, Tabert A, et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998;41:101–108
  23. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001;166:876–881
  24. Morgan PB, Hanlon AL, Horwitz EM, et al. Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy. Cancer. 2007;110:68–80
  25. Eade TN, Hanlon AL, Horwitz EM, et al. What dose of external-beam radiation is high enough for prostate cancer?. Int J Radiat Oncol Biol Phys. 2007;68:682–689

 Note—An online CME test for this article can be taken at http://asro.astro.org under Continuing Education.

 Conflict of interest: none.

PII: S0360-3016(07)04242-3

doi: 10.1016/j.ijrobp.2007.09.020

International Journal of Radiation Oncology * Biology * Physics
Volume 71, Issue 1 , Pages 16-22 , 1 May 2008

Article Tools

* Image Usage & Resolution